Clinical Trial

Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.

Study acronym: Bethesda3
Unknown
View on ClinicalTrials.gov →
Summary
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology. The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology. Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06539702
Lead Sponsor Saglik Bilimleri Universitesi
Conditions Blood Platelet Disorder, BRAF V600E, Thyroid Nodule, Cytologic Atypia
Enrollment 120 participants
Start Date 2024-07-20
Primary Completion 2024-08-06 (estimated)
Study Completion 2024-08-15 (estimated)
Updated on ClinicalTrials.gov 2024-08-06